-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Reiterates Buy on Cartesian Therapeutics, Maintains $40 Price Target

Benzinga·06/09/2026 16:53:48
Listen to the news
Needham analyst Gil Blum reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $40 price target.